Phase 2b study of diluted polyvicanone iodine in Veloce's new DMSO solvent system yielded positive results

yesterday (October 8), Veloce BioPharma, LLC ("Veloce")," announced positive results from its Phase 2 b study on dilution of polyvione iodine in the new DMSO solvent system, which is used for local treatment of chemotherapy-related enteritis, or nail pain and inflammation caused by chemotherapy side effectsthe safety, tolerance and effectiveness of the matrix in 102 chemotherapy-related patients with a phacolitis in 102 patients with chemotherapy-related enteritisresults showed that VBP-926 (2%) reached the primary end of the effectiveness of the grade improvement, according to the scale of the severity scale of enteritisConsistent with previously published case studies, VBP-926 has good tolerance at both doses, which can solve the morphological problems of affected nails and relieve symptoms2b results showed that the higher concentration of VBP-926 reached the main end of the effectivenessthe 2% dose of VBP-926 from baseline to end of treatment for the improved level of the nail level reached a statistically significant point in terms of changes in the scale of the scale of the severity scale of metagroheitis (p.0003)No serious adverse events associated with treatment occurredAdverse events are not very serious and can be recovered when treatment is stoppedVeloceVeloce is a clinical-stage bio
pharmaceutical(The Company(focusing on the development of topical therapies to address unmet needs in the field of skin and eye diseases)